OR WAIT null SECS
European bio/pharma companies have no choice but to invest and adapt to the evolving industry needs.
Revolutionary therapies restructure pharmaceutical manufacturing.
There are positive indications for future growth.
March 28, 2024
Univercells and Altamira Therapeutics are collaborating on nanoparticle-delivered mRNA vaccines, while Andelyn Biosciences and Grace Science are partnering on novel therapies for NGLY1 deficiency.
March 26, 2024
The Vacaville, Calif., site acquisition gives Lonza one of the largest biologics manufacturing sites for mammalian cell-based therapies worldwide.
March 25, 2024
Webinar Date/Time: Thu, Apr 18, 2024 9:00 AM EDT
Webinar Date/Time: Tue, Apr 16, 2024 11:00 AM EDT
Webinar Date/Time: Thu, Apr 25, 2024 11:00 AM EDT
March 22, 2024
AstraZeneca’s acquisition of Amolyt Pharma includes eneboparatide, a Phase III therapeutic peptide for the treatment of hypoparathyroidism.
CDMO White Raven aims to reduce contamination risk and gain the capability to handle multiple product formats with the installation of Cytiva’s SA25 Aseptic Filling Workcell.
March 21, 2024
Webinar Date/Time: Wed, May 8, 2024 11:00 AM EDT
March 20, 2024
FDA's approval makes Orchard Therapeutics' Lenmeldy (atidarsagene autotemcel) the first gene therapy approved to treat pediatric metachromatic leukodystrophy in the US.
March 18, 2024
Cellares CEO Fabian Gerlinghaus discusses the nuts and bolts of counterflow centrifugal elutriation and electroporation innovations and optimization, while hinting at big news on future release testing of products, as a product itself.